Prognostic value of preoperative 18F-FDG PET/CT for primary head and neck squamous cell carcinoma.

Advanced Search

Young-Hoon Joo, Ie-Ryung Yoo, Kwang-Jae Cho, Jun-Ook Park, In-Chul Nam, Chung-Soo Kim, Min-Sik Kim

Author Information

Young-Hoon Joo: Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 505 Banpodong Seochogu, Seoul, 137-040, Republic of Korea.

PMID: 23949547 DOI: 10.1007/s00405-013-2605-y

(18)F-FDG PET/CT is clinically useful in the initial staging and follow-up of patients with head and neck squamous cell carcinoma (HNSCC). We studied the potential prognostic significance of preoperative (18)F-FDG PET/CT in HNSCC. The medical records of 294 patients who underwent preoperative (18)F-FDG PET/CT for HNSCC were retrospectively reviewed. The median SUVmax of the primary lesions (SUVmax-p) and cervical lymph nodes (SUVmax-n) was 7.98 ± 5.04 (range 1.2-28.7) and 3.34 ± 3.70 (range 1.0-20.4), respectively. There was a significant difference between with and without recurrence in SUVmax-p (11.14 ± 5.36 vs. 6.78 ± 4.35, p < 0.001) and SUVmax-n (5.60 ± 4.22 vs. 1.75 ± 1.46, p < 0.001). The cut-off values of SUVmax-p and SUVmax-n in the context of recurrence and cancer-related death were 8.5 and 3.5. The 5-year disease-free survival of patients with SUVmax-p < 8.5 and SUVmax-n < 3.5 was 79 and 79%, respectively, whereas that of patients with SUVmax-p ≥ 8.5 and SUVmax-n ≥ 3.5 was 39 and 30 %, respectively. Multivariate analysis confirmed the significant association between 5-year disease-free survival and SUVmax-p ≥ 8.5 (hazard ratio (HR) 2.68, p < 0.001) and SUVmax-n ≥ 3.5 (HR 2.29, p = 0.007). Furthermore, SUVmax-p ≥ 8.5 (HR 3.20, p = 0.012) and SUVmax-n ≥ 3.5 (HR 2.14, p < 0.001) were associated with 5-year overall survival. (18)F-FDG PET/CT cut-off values of SUVmax-p ≥ 8.5 or SUVmax-n ≥ 3.5 are associated with a recurrence and survival in HNSCC.

Head Neck. 2005 Oct;27(10):843-50 [PMID: 16161069]
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1295-300 [PMID: 15275712]
Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):764-71 [PMID: 18835509]
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 [PMID: 22237781]
J Clin Oncol. 2002 Mar 1;20(5):1398-404 [PMID: 11870185]
Head Neck. 1998 Oct;20(7):588-94 [PMID: 9744457]
J Clin Oncol. 2002 Oct 15;20(20):4199-208 [PMID: 12377963]
J Clin Oncol. 2006 Sep 20;24(27):4371-6 [PMID: 16983105]
J Nucl Med. 2007 May;48(5):752-7 [PMID: 17475963]
J Nucl Med. 2005 Jul;46(7):1136-43 [PMID: 16000282]
Cancer. 2003 Feb 15;97(4):1015-24 [PMID: 12569601]
Head Neck. 2002 Feb;24(2):115-26 [PMID: 11891941]
J Nucl Med. 2003 Jul;44(7):1044-50 [PMID: 12843218]
Auris Nasus Larynx. 2009 Apr;36(2):192-8 [PMID: 18606510]
Radiology. 1993 Dec;189(3):847-50 [PMID: 8234714]
J Nucl Med. 1997 Dec;38(12):1907-11 [PMID: 9430467]
Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86 [PMID: 15375804]
Head Neck. 2009 Feb;31(2):195-201 [PMID: 19107945]
Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):571-8 [PMID: 11597795]
J Nucl Med. 1993 Jan;34(1):1-6 [PMID: 8418248]

Adult

Aged

Aged, 80 and over

Carcinoma, Squamous Cell

Cohort Studies

Disease-Free Survival

Female

Fluorodeoxyglucose F18

Head and Neck Neoplasms

Humans

Laryngeal Neoplasms

Lymph Nodes

Male

Middle Aged

Mouth Neoplasms

Multimodal Imaging

Multivariate Analysis

Neck

Pharyngeal Neoplasms

Positron-Emission Tomography

Prognosis

Proportional Hazards Models

Radiopharmaceuticals

Retrospective Studies

Squamous Cell Carcinoma of Head and Neck

Tomography, X-Ray Computed

Young Adult

Radiopharmaceuticals

Fluorodeoxyglucose F18

Journal Article

OpenLB
Open Library of Bioscience